{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-23-000069","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2023-11-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.778882+00:00","generated_at":"2026-06-07T21:24:04.542441+00:00","sec_items":["1.01","7.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AnaptysBio licenses global rights to BDCA2 modulator antibody portfolio from Centessa for $7M upfront","bullets":["Upfront cash payment of $7M ($4M license fee + $3M for GMP supply of ANB101).","Centessa eligible for $10M milestone at first Phase 3 start and low single-digit royalties.","Anaptys plans to file IND for ANB101 in H2 2024; ANB033 IND expected H1 2024.","Reiterates year-end 2023 cash of $400–410M and cash runway through end of 2026.","ANB101 targets BDCA2 on plasmacytoid dendritic cells for autoimmune/inflammatory diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-23-000069","json":"https://secwatch.observer/filing/0001370053-23-000069.json","markdown":"https://secwatch.observer/filing/0001370053-23-000069.md","text":"https://secwatch.observer/filing/0001370053-23-000069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000069/0001370053-23-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000069/anab-20231124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:24:04.542441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"568f2fbc949027cb68d8a1a9baa37d0a0b2c5f02","claim":"ANAPTYSBIO, INC entered into License Agreement with Centessa Pharmaceuticals (UK) Limited valued at $7 million (effective 2023-11-24).","evidence_excerpt":"On November 24, 2023, AnaptysBio, Inc. (“ Anaptys ”) entered into a License Agreement (the “ License Agreement ”) with Centessa Pharmaceuticals (UK) Limited (“ Centessa ”) pursuant to which Centessa granted to Anaptys an exclusive worldwide license under Centessa’s rights to the blood dendritic cell antigen 2 (BDCA2) modulator antibody portfolio, including lead asset CBS004 and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1370053/000137005323000069/0001370053-23-000069-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Centessa Pharmaceuticals (UK) Limited"},{"label":"Value","value":"$7 million"},{"label":"Effective","value":"2023-11-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}